Found: 16
Select item for more details and to access through your institution.
A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Adjuvant and Neoadjuvant Options in Resectable Gastric Cancer: Is There an Optimal Treatment Approach?
- Published in:
- Current Oncology Reports, 2015, v. 17, n. 4, p. 1, doi. 10.1007/s11912-015-0442-4
- By:
- Publication type:
- Article
Is it Time Yet for Adjuvant Immunotherapy for Patients with DNA Mismatch Repair Deficient Gastric Cancer?
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 1, p. 142, doi. 10.1007/s10637-020-00962-x
- By:
- Publication type:
- Article
Prediction of 177 Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68 Ga-DOTATATE PET/CT.
- Published in:
- Cancers, 2024, v. 16, n. 1, p. 200, doi. 10.3390/cancers16010200
- By:
- Publication type:
- Article
Evolving Standards of Care for Neoadjuvant and Adjuvant Therapy in Esophageal, Gastroesophageal Junction, and Gastric Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 20, p. 784
- By:
- Publication type:
- Article
The efficacy and safety of definitive concurrent chemoradiotherapy for non‐operable esophageal cancer.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 4, p. 1275, doi. 10.1002/cam4.3724
- By:
- Publication type:
- Article
Integrated Capecitabine–Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective Study.
- Published in:
- CardioVascular & Interventional Radiology, 2024, v. 47, n. 1, p. 60, doi. 10.1007/s00270-023-03614-8
- By:
- Publication type:
- Article
Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 3, p. e212274, doi. 10.1001/jamanetworkopen.2021.2274
- By:
- Publication type:
- Article
<sup>68</sup>Ga‐DOTATATE Positron Emission Tomography‐Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors.
- Published in:
- Oncologist, 2021, v. 26, n. 1, p. 21, doi. 10.1634/theoncologist.2020-0165
- By:
- Publication type:
- Article
Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.‐Based Neuroendocrine Tumor Cohort.
- Published in:
- Oncologist, 2020, v. 25, n. 7, p. 572, doi. 10.1634/theoncologist.2019-0743
- By:
- Publication type:
- Article
A New Era for the Systemic Therapy of Neuroendocrine Tumors.
- Published in:
- Oncologist, 2012, v. 17, n. 3, p. 326, doi. 10.1634/theoncologist.2011-0356
- By:
- Publication type:
- Article
Update in hematology and oncology: evidence published in 2012.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Update in Hematology and Oncology: Evidence Published in 2012.
- Published in:
- Annals of Internal Medicine, 2013, v. 158, n. 10, p. 755, doi. 10.7326/0003-4819-158-10-201305210-00105
- By:
- Publication type:
- Article
Association between timely targeted treatment and outcomes in patients with metastatic HER2‐overexpressing gastroesophageal adenocarcinoma.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 9, p. 1853, doi. 10.1002/cncr.34117
- By:
- Publication type:
- Article
Adherence to and determinants of guideline‐recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 14, p. 2562, doi. 10.1002/cncr.33514
- By:
- Publication type:
- Article